Can mutations in mitochondria lead to autism?

Can mutations in mitochondria lead to autism?

Early research shows how mild defects in mitochondria can lead to behaviors similar to those seen in autism
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00

PHILADELPHIA—A team of researchers at the Children’s Hospital of Philadelphia (CHOP) has demonstrated that autism spectrum disorder (ASD) could be caused by defects in the mitochondria of brain cells. The research findings have been published online in Proceedings of the National Academy of Sciences.

Multiple studies have revealed hundreds of mutations associated with autism spectrum disorder, but as yet there is no consensus on how these genetic changes cause the condition. Biochemical and physiological analyses have suggested that mitochondrial deficiencies could be a potential cause, and recent studies have shown that variants of mitochondrial DNA (mtDNA) are associated with autism spectrum disorder.

“Autism spectrum disorder is highly genetically heterogeneous, and many of the previously identified copy number and loss of function variants could have an impact on the mitochondria,” said Dr. Douglas C. Wallace, director of the Center for Mitochondrial and Epigenomic Medicine and the Michael and Charles Barnett Endowed Chair in Pediatric Mitochondrial Medicine and Metabolic Diseases at CHOP, who is co-senior author of the study.

The team hypothesized that if defects in the mitochondria do predispose patients to ASD, then a mouse model in which relevant mtDNA mutations have been introduced should present with autism endophenotypes. In this model, the traits related to autism included behavioral, neurophysiological, and biochemical features.

The researchers — including co-first authors Dr. Tal Yardeni and Dr. Ana G. Cristancho, as well as co-senior author Dr. Eric D. Marsh, attending pediatric neurologist in the Division of Child Neurology at CHOP — introduced a mild missense mutation in the mtDNA ND6 gene into a mouse strain. The resulting mouse exhibited impaired social interactions, increased repetitive behaviors, and anxiety. These behavioral features are commonly associated with autism spectrum disorder. 

The team also noted aberrations in electroencephalograms, more seizures, and brain-region specific defects of mitochondrial function in the mouse model. But despite these observations, the researchers found no obvious changes in the brain’s anatomy. These findings suggest that mitochondrial energetic defects appear to be sufficient as a cause for autism.

“Our study shows that mild systemic mitochondrial defects can result in autism spectrum disorder without causing apparent neuroanatomical defects,” Wallace added. “These mutations appear to cause tissue-specific brain defects. While our findings warrant further study, there is reason to believe that this could lead to better diagnosis of autism, and potentially treatments directed toward mitochondrial function."

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Reliable fluid biomarkers strategies for clinical neuroscience research

Reliable fluid biomarkers strategies for clinical neuroscience research

Explore how validated fluid biomarker assays advance clinical research for neurological diseases.
A group of blue capsules is scattered on a bright yellow surface, with one capsule opened to reveal white powder inside.

Understanding drug impurities: types, sources, and analytical strategies

Unseen and often unexpected, drug impurities can slip in at every drug development stage, making their detection and control essential.
Laboratorian with a white coat and blue gloves pipettes green liquid into a beaker with multicolored liquids in beakers and tubes in the blue-tinged, sterile laboratory background.

Discovering cutting-edge nitrosamine analysis in pharmaceuticals

New tools help researchers detect and manage harmful nitrosamine impurities in drugs such as monoclonal antibodies.
Drug Discovery News March 2025 Issue
Latest IssueVolume 21 • Issue 1 • March 2025

March 2025

March 2025 Issue

Explore this issue